Sex Differences in Survival from Neuroendocrine Neoplasia in England 2012–2018: A Retrospective, Population-Based Study
Authors:
- Benjamin E. WhiteBWBenjamin E. White
- Beth RussellBRBeth Russell
- Sebastiaan RemmersSRSebastiaan Remmers
- Brian RousBRBrian Rous
- Kandiah ChandrakumaranKCKandiah Chandrakumaran
- Kwok F. WongKWKwok F. Wong
- Mieke Van HemelrijckMieke Van Hemelrijck
- Rajaventhan SrirajaskanthanRSRajaventhan Srirajaskanthan
- John K. RamageJRJohn K. Ramage
Open Access
Abstract
Pre-clinical studies have suggested sex hormone signalling pathways may influence tumorigenesis in neuroendocrine neoplasia (NEN). We conducted a retrospective, population-based study to compare overall survival (OS) between males and females with NEN. A total of 14,834 cases of NEN diagnosed between 2012 and 2018, recorded in England’s National Cancer Registry and Analysis Service (NCRAS), were analysed. The primary outcome was OS with 5 years maximum follow-up. Multivariable analysis, restricted mean survival time and mediation analysis were performed. Appendiceal, pulmonary and early-stage NEN were most commonly diagnosed in females; stomach, pancreatic, small intestinal, colonic, rectal and later-stage NEN were more often diagnosed in males. Females displayed increased survival irrespective of the stage, morphology or level of deprivation. On average, they survived 3.62 (95% CI 1.73–5.90) to 10.26 (6.6–14.45) months longer than males; this was statistically significant in NEN of the lung, pancreas, rectum and stomach (p < 0.001). The stage mediated improved survival in stomach, lung, and pancreatic NEN but not in rectal NEN. The reasons underlying these differences are not yet understood. Overall, females diagnosed with NEN tend to survive longer than males, and the stage at presentation only partially explains this. Future research, as well as prognostication and treatment, should consider sex as an important factor.Keywords
Funding Information
- Neuroendocrine Cancer UK (£10,000)
- Hampshire Hospitals NHS Foundation Trust and the National Institute for Health Research (£10,000)
This publication has 43 references indexed in Scilit:
- The rise of multiple imputation: a review of the reporting and implementation of the method in medical researchBMC Medical Research Methodology, 2015
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsAnnals of Oncology, 2015
- Diabetes, Smoking, Alcohol Use, and Family History of Cancer as Risk Factors for Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-AnalysisNeuroendocrinology, 2015
- Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomesCancer, 2014
- Expression of Estrogen-Induced Genes and Estrogen Receptor β in Pancreatic Neuroendocrine TumorsPancreas, 2014
- Androgen signalling and steroid receptor crosstalk in endocrine cancersEndocrine-Related Cancer, 2014
- Immunohistochemical Expression and Prognostic Value of ER, PR and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine TumorsNeuroendocrinology, 2011
- Contribution of smoking-related and alcohol-related deaths to the gender gap in mortality: evidence from 30 European countries: Table 1Tobacco Control, 2011
- Risk factors associated with neuroendocrine tumors: A U.S.‐based case–control studyInternational Journal of Cancer, 2008
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006